FDA postpones decision on weight-loss drug by 3 months

04/9/2012 | Reuters

The FDA told Vivus it won't rule on weight-loss pill Qnexa until July 17 because the agency needs extra time to look at the drugmaker's risk evaluation and mitigation strategy. In February, an advisory panel decided that Qnexa's benefits outweigh the risks.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX
PROGRAM MANAGER HEOR - 1300000APD
Abbott
Santa Clara, CA
FDA/Post Drug Approval Attorney
Quarles & Brady
Washington, DC